17 completed, 6 unknown, 2 recruiting, 2 terminated. 29 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 29 | Completed 17, Unknown 6, Recruiting 2, Terminated 2, Suspended 1, Withdrawn 1 |
| Phase 1 | 4 | Completed 3, Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Sarcoma, Soft Tissue: new trials by email Literature Review of Sarcoma, Soft Tissue trials Research Report on Sarcoma, Soft Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma Metformin Hydrochloride ER - Sarcoma Metastatic, Sarcoma, Soft Tissue | Phase 2 | Recruiting | Wake Forest University Health Sciences | 50 | 2026-03-04 | 2026-07-23 |
| A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma Recombinant anti-PD-1 humanized monoclonal antibody injection - Sarcoma, Soft Tissue | Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 30 | 2022-01-25 | 2022-01-14 |
| A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma 609A, doxorubicin hydrochloride - Sarcoma, Soft Tissue | Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 70 | 2021-12-30 | 2021-11-30 |
| The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma Sintilimab, Doxorubicin Hydrochloride, Ifosfamide - Sarcoma, Soft Tissue | Phase 2 | Unknown | Fudan University | 45 | 2020-04-08 | 2020-07-14 |
| Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients anlotinib - Sarcoma, Soft Tissue | Phase 2 | Unknown | Liaoning Cancer Hospital & Institute | 47 | 2019-05-20 | 2019-07-09 |
| Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma Nintedanib, Ifosfamide - Sarcoma, Soft Tissue | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 80 | 2017-07-07 | 2021-09-20 |
| Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma Dexrazoxane, Doxorubicin - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 73 | 2016-02-22 | 2023-11-07 |
| Study of Pazopanib Versus Placebo as Maintenance Therapy for Advanced Soft Tissue Sarcoma Pazopanib 800 mg, Placebo - Sarcoma, Soft Tissue | Phase 2 | Withdrawn | GlaxoSmithKline | 2015-06-01 | 2016-10-12 | |
| Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy Pazopanib - Sarcoma, Soft Tissue, Soft Tissue Sarcoma | Phase 2 | Completed | Washington University School of Medicine | 56 | 2015-04-08 | 2020-08-05 |
| Ifosfamide, Doxorubicin and Hypofractionated Radiotherapy in Neoadjuvant Sarcoma Treatment Doxorubicin, Ifosfamide, radiotherapy - Sarcoma, Soft Tissue | Phase 2 | Unknown | AC Camargo Cancer Center | 70 | 2015-03-01 | 2016-06-24 |
| Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients Trabectedin, Radiotherapy - Liposarcoma, Myxoid, Sarcoma, Soft Tissue | Phase 1 / Phase 2 | Recruiting | Grupo Espanol de Investigacion en Sarcomas | 199 | 2014-11-01 | 2023-05-31 |
| Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors nab-paclitaxel - Neuroblastoma, Rhabdomyosarcoma | Phase 1 / Phase 2 | Completed | Celgene | 107 | 2013-12-04 | 2019-12-27 |
| A Study of Olaratumab in Soft Tissue Sarcoma Olaratumab, doxorubicin - Sarcoma, Soft Tissue | Phase 1 / Phase 2 | Completed | Eli Lilly and Company | 148 | 2010-10-01 | 2017-04-14 |
| A Study of LY573636-Sodium in the Treatment of Patients With Metastatic Soft Tissue Sarcoma LY573636-sodium - Sarcoma, Soft Tissue | Phase 2 | Completed | Eli Lilly and Company | 101 | 2007-08-01 | 2019-09-18 |
| Sunitinib in Certain Subtypes of Soft Tissue Sarcomas Sunitinib - Sarcoma, Soft Tissue | Phase 2 | Terminated | Columbia University | 10 | 2007-04-01 | 2019-11-04 |
| BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas Sorafenib (BAY-43-9006) - Sarcoma, Soft Tissue | Phase 2 | Completed | Istituto Clinico Humanitas | 69 | 2006-11-01 | 2010-09-02 |
| TLC D-99 and Ifosfamide in Metastatic Soft Tissue Sarcoma Patients combination of TLC D-99 and Ifosfamide - Sarcoma, Soft Tissue | Phase 1 / Phase 2 | Completed | Istituto Clinico Humanitas | 36 | 2006-09-01 | 2009-12-18 |
| Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis Laboratory Assay, Mick Assay - Breast Neoplasms, Lung Neoplasms | Phase 2 / Phase 3 | Completed | Pierian Biosciences | 150 | 2006-09-01 | 2012-01-26 |
| Pazopanib In Patients With Relapsed Or Refractory Soft Tissue Sarcoma pazopanib - Sarcoma, Soft Tissue | Phase 2 | Completed | GlaxoSmithKline | 148 | 2005-11-01 | 2016-02-03 |
| Alimta Plus Gemcitabine for Advanced Sarcoma Alimta, Gemcitabine - Sarcoma, Soft Tissue | Phase 2 | Completed | Columbia University | 12 | 2005-08-01 | 2020-08-25 |
Showing 20 of 29. Sign in to see all of them.
Sarcoma (29) · Leiomyosarcoma (4) · Liposarcoma (3) · Dermatofibrosarcoma (2) · Fibrosarcoma (2) · Neoplasm Metastasis (2) · Osteosarcoma (2) · Sarcoma, Synovial (2) · Breast Neoplasms (1) · Hemangiosarcoma (1) · Histiocytoma (1) · Histiocytoma, Malignant Fibrous (1) · Liposarcoma, Myxoid (1) · Lung Neoplasms (1) · Melanoma (1)
Neoplasms by Histologic Type (29) · Neoplasms, Connective and Soft Tissue (29) · Neoplasms (28) · Neoplasms, Muscle Tissue (5) · Neoplasms, Connective Tissue (4) · Neoplasms, Adipose Tissue (3) · Neoplasms by Site (2) · Neoplasms, Bone Tissue (2) · Neoplasms, Fibrous Tissue (2) · Neoplasms, Nerve Tissue (2) · Neoplastic Processes (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Skin Diseases (2) · Skin and Connective Tissue Diseases (2)
Doxorubicin (7) · Ifosfamide (6) · pazopanib (3) · Carboplatin (2) · Gemcitabine (2) · Radiotherapy (2) · 130-nm albumin-bound paclitaxel (1) · Albumin-Bound Paclitaxel (1) · Bendamustine Hydrochloride (1) · Dexrazoxane (1) · Docetaxel (1) · Drug Therapy (1) · Etoposide (1) · Metformin (1) · N-((5-bromo-2-thienyl)sulfonyl)-2,4-dichlorobenzamide (1)
Columbia University (2) · Eli Lilly and Company (2) · GlaxoSmithKline (2) · Istituto Clinico Humanitas (2) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (2) · University Hospital Tuebingen (2) · Washington University School of Medicine (2) · AC Camargo Cancer Center (1) · Abbott (1) · Celgene (1) · Cooperative Weichteilsarkom Study Group (1) · Dana-Farber Cancer Institute (1) · Enzon Pharmaceuticals, Inc. (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fudan University (1)
United States (13) · China (4) · France (4) · Germany (4) · Italy (4) · Spain (4) · United Kingdom (3) · Belgium (2) · Netherlands (2) · Argentina (1) · Brazil (1) · Canada (1) · Hungary (1) · Lithuania (1) · Poland (1)
Armando Santoro, MD (2) · Brian A Van Tine, M.D., Ph.D. (2) · Joerg T. Hartmann, MD (2) · Robert N Taub, MD, PhD (2) · Ademar Lopes, Phd (1) · Alexander Zweibach, MD, PhD (1) · Cary Presant, MD (1) · Ileana Elias, M.D. (1) · Joerg T Hartmann, MD (1) · Karl Rogers, MD (1) · Li Shenglong, master (1) · Megan Jagosky, MD (1)
PMID 18268546, PMID 22067397, PMID 22539091, PMID 24504442, PMID 26378637, PMID 27291997, PMID 27544129, PMID 28546135, PMID 31143880, PMID 31401903, PMID 32077895, PMID 32554315, PMID 32827353, PMID 33798613, PMID 34062484
2004 (1), 2016 (1)